{
    "nctId": "NCT01770353",
    "briefTitle": "MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment",
    "officialTitle": "A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment",
    "overallStatus": "COMPLETED",
    "conditions": "Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 45,
    "primaryOutcomeMeasure": "Pilot Phase: Tumour Levels of Irinotecan and SN-38 at Cycle 1 Day 4",
    "eligibilityCriteria": "Inclusion Criteria:\n\nAll subjects:\n\n* Pathologically confirmed diagnosis of solid tumors\n* Metastatic disease\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1\n* Adequate bone marrow, hepatic and renal function\n* Normal Electrocardiogram (ECG)\n* 18 years of age or above\n* Able to understand and sign informed consent\n\nPilot study only:\n\n- CRC, TNBC, ER/PR Breast Cancer, NSCLC, Pancreatic Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal Junction (GEJ) adenocarcinoma, Head and Neck Cancer\n\nExpansion Phase Additional Criteria:\n\n* Locally advanced or metastatic breast cancer\n* Received at least one cytotoxic therapy in the locally advanced and metastatic setting\n* Received \u2264 5 prior lines of chemotherapy in the metastatic setting\n* Candidate for chemotherapy\n\nExpansion Phase Cohort 3 additional inclusion criteria:\n\n* Breast cancer with active brain metastasis\n* Neurologically stable\n\nExclusion Criteria:\n\n* Active Central nervous system (CNS) metastasis (applies to pilot phase and expansion phase cohort 1 and 2 only)\n* Clinically significant GI disorders\n* Prior irinotecan or bevacizumab therapy within last 6 months and for Expansion Phase patients, have received any prior treatment with Topol inhibitor\n* Known hypersensitivity to MM-398 or ferumoxytol\n* Inability to undergo MRI\n* Active infection\n* Pregnant or breast feeding\n* Prior chemotherapy administered within 3 weeks, or within a time interval less than at least 5 half-lives of the agent, whichever is longer, prior to the first scheduled day of dosing in this study\n* Received radiation therapy in the last 14 days\n* Treated with parenteral iron in the previous 4 weeks",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}